Actinium Announces $15.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering Mar 5, 2018
Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations Feb 28, 2018
Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B Feb 27, 2018
Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and Amendment to Pricing Terms of its Rights Offering Feb 26, 2018
Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations Feb 20, 2018
Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML Feb 12, 2018
Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record Feb 12, 2018
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation Feb 8, 2018
